Skip to content
10-Q

Quarterly Report

Silo Pharma, Inc. SILO

0001213900-25-041519

← back to feed
Filed
May 9, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 8, 2025 4.48M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $3.14M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $3.91M
Current Liabilities Q1 2025 · Mar 31, 2025 $1.19M
Current Liabilities Q1 2025 · Dec 31, 2024 $1.66M
Total Liabilities Q1 2025 · Mar 31, 2025 $1.89M
Total Liabilities Q1 2025 · Dec 31, 2024 $2.38M
Current Assets Q1 2025 · Mar 31, 2025 $5.6M
Current Assets Q1 2025 · Dec 31, 2024 $7.11M
Total Assets Q1 2025 · Mar 31, 2025 $5.9M
Total Assets Q1 2025 · Dec 31, 2024 $7.41M
Shares Diluted Q1 2025 · Mar 31, 2024 2.87M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$838.18K
Short Term Investments Q1 2025 · Mar 31, 2024 $4.08M
Short Term Investments Q1 2025 · Dec 31, 2023 $4.14M
Stockholders Equity Q1 2025 · Mar 31, 2024 $5.29M
Stockholders Equity Q1 2025 · Dec 31, 2023 $6.18M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.28
Eps Basic Q1 2025 · Mar 31, 2024 −$0.28
Rd Expense Q1 2025 · Mar 31, 2024 $318.24K
Net Income Q1 2025 · Mar 31, 2024 −$801.67K
Operating Income Q1 2025 · Mar 31, 2024 −$879.51K
Gross Profit Q1 2025 · Mar 31, 2024 $16.57K
Cost Of Revenue Q1 2025 · Mar 31, 2024 $1.46K
Revenue Q1 2025 · Mar 31, 2024 $18.03K
Stock Repurchased Q1 2025 · Jan 9, 2024 $1M